The Biology of Chronic Myelogenous Leukemia Progression: Who, What, Where, and Why?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The Biology of Chronic Myelogenous Leukemia Progression: Who, What, Where, and Why?

Published:2011-10 Issue:5 Volume:25 Page:967-980
ISSN:0889-8588
Container-title:Hematology/Oncology Clinics of North America
language:en
Short-container-title:Hematology/Oncology Clinics of North America

Author:

Radich Jerald P.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference80 articles.

1. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis;Branford;Blood,2003

2. ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia

3. Chronic myeloid leukaemia as a model of disease evolution in human cancer;Melo;Nat Rev Cancer,2007

4. Chronic myeloid leukemia: mechanisms of blastic transformation;Perrotti;J Clin Invest,2010

5. Chronic myelogenous leukemia;O’Brien;J Natl Compr Canc Netw,2007

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding and Monitoring Chronic Myeloid Leukemia Blast Crisis: How to Better Manage Patients;Cancer Management and Research;2021-06

2. BCR–ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy;Cell Death & Disease;2017-10

3. The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias;Oncotarget;2016-08-22

4. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy;Leukemia;2016-08-18

5. New Insights Into Biology of Chronic Myeloid Leukemia: Implications in Therapy;Current Cancer Drug Targets;2013-08-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3